MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

Blood
Sandrine SanderThomas Wirth

Abstract

The MYC oncogene, which is commonly mutated/amplified in tumors, represents an important regulator of cell growth because of its ability to induce both proliferation and apoptosis. Recent evidence links MYC to altered miRNA expression, thereby suggesting that MYC-regulated miRNAs might contribute to tumorigenesis. To further analyze the impact of MYC-regulated miRNAs, we investigated a murine lymphoma model harboring the MYC transgene in a Tet-off system to control its expression. Microarray-based miRNA expression profiling revealed both known and novel MYC targets. Among the miRNAs repressed by MYC, we identified the potential tumor suppressor miR-26a, which possessed the ability to attenuate proliferation in MYC-dependent cells. Interestingly, miR-26a was also found to be deregulated in primary human Burkitt lymphoma samples, thereby probably being of clinical relevance. Although today only few miRNA targets have been identified in human disease, we could show that ectopic expression of miR-26a influenced cell cycle progression by targeting the bona fide oncogene EZH2, a Polycomb protein and global regulator of gene expression yet unknown to be regulated by miRNAs. Thus, in addition to directly targeting protein-coding genes,...Continue Reading

References

Dec 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·R TaubP Leder
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·M B EisenD Botstein
Jan 10, 2001·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·M Gonzales
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·V G TusherG Chu
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Oct 3, 2002·Nature Reviews. Cancer·Stella PelengarisGerard Evan
Oct 11, 2002·Nature·Sooryanarayana VaramballyArul M Chinnaiyan
May 2, 2003·Nature Reviews. Cancer·Dean W Felsher
Feb 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Apr 16, 2004·The New England Journal of Medicine·Lars BullingerJonathan R Pollack
Apr 20, 2004·International Journal of Cancer. Journal International Du Cancer·Dragan MarinkovicThomas Wirth
Apr 24, 2004·Science·Soraya YektaDavid P Bartel
Jul 2, 2004·Nature Reviews. Cancer·Jagruti H PatelSteven B McMahon
Jul 22, 2004·Blood·Kristie A BlumJohn C Byrd
Oct 13, 2004·Nucleic Acids Research·Dragan MarinkovicThomas Wirth
Mar 16, 2005·Cell·Steven M JohnsonFrank J Slack
Jun 10, 2005·Nature·Lin HeScott M Hammond
Jun 10, 2005·Nature·Jun LuTodd R Golub
Jun 10, 2005·Nature·Kathryn A O'DonnellJoshua T Mendell
Aug 3, 2005·Nature Reviews. Molecular Cell Biology·Sovana Adhikary, Martin Eilers
Aug 27, 2005·Cell·Shveta BaggaAmy E Pasquinelli
Oct 28, 2005·The New England Journal of Medicine·George Adrian CalinCarlo M Croce
Nov 30, 2005·Nucleic Acids Research·Caifu ChenKarl J Guegler
Feb 18, 2006·Science·Antonio J GiraldezAlexander F Schier
Mar 25, 2006·Nature Reviews. Cancer·Aurora Esquela-Kerscher, Frank J Slack
Apr 19, 2006·Genes & Development·Adrian P BrackenKristian Helin
Aug 1, 2006·Nature Genetics·Michael DewsAndrei Thomas-Tikhonenko
Oct 25, 2006·Nature Reviews. Cancer·Anke Sparmann, Maarten van Lohuizen
Dec 16, 2006·Nucleic Acids Research·Michael HölzelDirk Eick
Feb 27, 2007·Cell·Bernd SchuettengruberGiacomo Cavalli
Jun 2, 2007·Molecular Cell·Tsung-Cheng ChangJoshua T Mendell
Jun 8, 2007·Nature·Lin HeGregory J Hannon
Jun 29, 2007·Nature·David Dominguez-SolaRiccardo Dalla-Favera
Dec 11, 2007·Nature Genetics·Tsung-Cheng ChangJoshua T Mendell

❮ Previous
Next ❯

Citations

Apr 27, 2013·Frontiers of Medicine·Sandy Leung-Kuen AuChun-Ming Wong
Sep 27, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Miguel A VarelaMatthew J A Wood
Jan 15, 2011·Leukemia·C BödörJ Fitzgibbon
Feb 17, 2009·Nature Genetics·Sonia A MeloManel Esteller
Jan 28, 2010·Nature Genetics·Eva Martinez-Garcia, Jonathan D Licht
Sep 24, 2009·Human Reproduction Update·E Maria C Ohlsson TeagueM Louise Hull
Dec 21, 2010·American Journal of Respiratory and Critical Care Medicine·Mitsuhiro YamadaClaire M Doerschuk
Dec 24, 2010·Journal of Dental Research·D Bayarsaihan
Jul 23, 2011·Genes & Cancer·Cheryl M KohAngelo M De Marzo
Jun 3, 2011·Blood·Santiago Montes-MorenoMiguel A Piris
May 25, 2013·Blood·Yanwen JiangRita Shaknovich
May 31, 2011·Cancer Cell International·Jessica CarlssonKarin Klinga-Levan
Dec 20, 2012·RNA·Keerthana KrishnanSean M Grimmond

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis